Repeated administration of autologous tumor-infiltrating lymphocytes (LM103 infusion) alongside immune checkpoint inhibitors results in sustained tumor regression in a patient with advanced mucosal melanoma: a case study and review of existing literature - Summary - MDSpire
Advertisement
Repeated administration of autologous tumor-infiltrating lymphocytes (LM103 infusion) alongside immune checkpoint inhibitors results in sustained tumor regression in a patient with advanced mucosal melanoma: a case study and review of existing literature
To evaluate the safety and efficacy of repeated autologous tumor-infiltrating lymphocyte (TIL) therapy in a patient with advanced mucosal melanoma who had progressed on multiple lines of immunotherapy, including specific agents.
Key Findings:
The patient achieved a partial response (PR) at 6 weeks and a complete response (CR) at 12 weeks post-infusion, indicating significant therapeutic potential.
Subsequent TIL infusions resulted in stable disease (SD) and another PR, demonstrating repeated clinical responses.
Manageable adverse events were observed and resolved shortly after TIL treatments, suggesting a favorable safety profile.
Longitudinal immune monitoring indicated sustained systemic immune activation, which may correlate with clinical outcomes.
Interpretation:
Multiple autologous TIL therapies can induce repeated clinical and immunological responses in heavily pretreated melanoma patients, suggesting a feasible treatment strategy.
Limitations:
This is a single case study, limiting generalizability and necessitating caution in interpreting results.
Further research is needed to define optimal dosing, timing, and patient selection for TIL therapy, which could enhance treatment efficacy.
Conclusion:
The case highlights the potential of repeated TIL infusions in enhancing treatment outcomes for advanced melanoma, warranting further investigation in larger trials to validate these findings and optimize treatment protocols.
